-- 根据海关周二公布的数据,中国3月份贸易顺差为511.3亿美元。 据Investing.com报道,这一数字低于2月份的2136.2亿美元顺差,也低于分析师此前预测的1075亿美元。 荷兰国际集团(ING)分析师周二在一份报告中指出,以本币计算,贸易顺差同比下降4.8%。 荷兰国际集团表示,以本币计算的贸易顺差下降也可能影响将于周四公布的中国GDP数据。 海关数据显示,3月份出口同比增长2.5%,达到3210亿美元。据Investing.com报道,这一增速低于此前预测的8.3%,也低于1-2月份21.8%的增幅。 荷兰国际集团(ING)分析师表示,对美出口同比下降14.6%,但预计未来几个月降幅将有所缓解。 荷兰国际集团表示:“由于预计来自美国的拖累将会缓解——假设没有新的关税冲击(虽然不能完全排除这种可能性)——外部需求仍将是今年增长的重要驱动力。” 据多家媒体报道,当月进口额同比增长27.8%至2699亿美元,超出预期,高于1-2月19.8%的增幅。 荷兰国际集团分析师表示,进口激增主要归因于科技产品价格上涨,这带动了亚太其他地区“惊人的出口增长”。 分析师指出,中国半导体进口量同比增长11%,进口额同比增长45%。 荷兰国际集团(ING)表示,该数据并未计入伊朗战争的影响,因为原油进口量同比增长8.9%,但进口额同比下降4.7%。 该行表示,未来几个月能源价格上涨可能会进一步加速进口。 本季度贸易顺差达到2643亿美元。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.